If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
Anti-Human CD20 Therapeutic Antibody (Arzerra). Recombinant monoclonal antibody to Human CD20. Ofatumumab (trade name Arzerra, also known as HuMax-CD20) is a human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating Follicular non-Hodgkin's lymphoma, Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia. This makes ofatumumab the first marketing application for an antibody, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.
Immunogen
Hmuan CD20 transfected NS/O cells.
Other Names
Ofatumumab;arzerra;679818-59-8;GSK1841157;HuMax-CD20;2F2;Arzerra;HuMax-CD20;MS4A1;membrane-spanning 4-domains, subfamily A, member 1;CD20;B-lymphocyte antigen CD20;B1;Bp35;MS4A2;CD20 antigen;CD20 receptor;leukocyte surface antigen Leu-16;B-lymphocyte cell